FDA seeks more COI (conflict of interest) information from advisory panellists
This article was originally published in Clinica
Executive Summary
Experts who participate on US FDA product specific advisory panels are to be asked to provide more detailed information about their potential financial conflicts than they have in the past. Under a new conflict of interest (COI) policy, experts must categorise the size of their stock holdings, their consulting fees, their contracts and grants and their teaching speaking or writing fees. The disclosures will identify whether the interest is related to the sponsor or competitor that markets a competing product and whether the expert worked on the competing product or not.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.